|
Written by Onyx Pharmaceuticals, Inc.
|
|
Saturday, 10 December 2011 |
|
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced summaries of three poster presentations of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA. |
|
Read more...
|